182 related articles for article (PubMed ID: 17152347)
21. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M
Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720
[TBL] [Abstract][Full Text] [Related]
22. Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Lassen U; Miller WH; Hotte S; Evans TR; Kollmansberger C; Adamson D; Nielsen DL; Spicer J; Chen E; Meyer T; Brown K; Rafi R; Sawyer MB
Cancer Chemother Pharmacol; 2013 Feb; 71(2):543-9. PubMed ID: 23196640
[TBL] [Abstract][Full Text] [Related]
23. Rifampicin reduces plasma concentrations of celiprolol.
Lilja JJ; Niemi M; Neuvonen PJ
Eur J Clin Pharmacol; 2004 Jan; 59(11):819-24. PubMed ID: 14614579
[TBL] [Abstract][Full Text] [Related]
24. Effect of prokinetic agents, cisapride and metoclopramide, on the bioavailability in humans and intestinal permeability in rats of ranitidine, and intestinal charcoal transit in rats.
Lee HT; Lee YJ; Chung SJ; Shim CK
Res Commun Mol Pathol Pharmacol; 2000; 108(5-6):311-23. PubMed ID: 11958284
[TBL] [Abstract][Full Text] [Related]
25. Potential pharmacokinetic effect of rifampicin on enrofloxacin in broilers: Roles of P-glycoprotein and BCRP induction by rifampicin.
Guo M; Dai X; Hu D; Zhang Y; Sun Y; Ren W; Wang L
Poult Sci; 2016 Sep; 95(9):2129-35. PubMed ID: 27118859
[TBL] [Abstract][Full Text] [Related]
26. Effects of sinapic acid on hepatic cytochrome P450 3A2, 2C11, and intestinal P-glycoprotein on the pharmacokinetics of oral carbamazepine in rats: Potential food/herb-drug interaction.
Raish M; Ahmad A; Ansari MA; Alkharfy KM; Ahad A; Al-Jenoobi FI; Al-Mohizea AM; Khan A; Ali N
Epilepsy Res; 2019 Jul; 153():14-18. PubMed ID: 30927680
[TBL] [Abstract][Full Text] [Related]
27. Regional difference in P-glycoprotein function in rat intestine.
Iida A; Tomita M; Hayashi M
Drug Metab Pharmacokinet; 2005 Apr; 20(2):100-6. PubMed ID: 15855720
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
Stass H; Böttcher MF; Ochmann K
Clin Pharmacokinet; 2001; 40 Suppl 1():39-48. PubMed ID: 11352441
[TBL] [Abstract][Full Text] [Related]
29. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
30. Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats.
Tian X; Chang Y; Wei J; Liu R; Wang L; Zhang J; Zhang X
J Pharm Pharmacol; 2019 May; 71(5):788-796. PubMed ID: 30663770
[TBL] [Abstract][Full Text] [Related]
31. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers.
Garg V; Chandorkar G; Yang Y; Adda N; McNair L; Alves K; Smith F; van Heeswijk RP
Br J Clin Pharmacol; 2013 Feb; 75(2):431-9. PubMed ID: 22642697
[TBL] [Abstract][Full Text] [Related]
32. Effect of hydroxyzine on the transport of etoposide in rat small intestine.
Kan WM; Liu YT; Hsiao CL; Shieh CY; Kuo JH; Huang JD; Su SF
Anticancer Drugs; 2001 Mar; 12(3):267-73. PubMed ID: 11290874
[TBL] [Abstract][Full Text] [Related]
33. Comparison of two compartmental models for describing ranitidine's plasmatic profiles.
Schaiquevich P; Niselman A; Rubio M
Pharmacol Res; 2002 May; 45(5):399-405. PubMed ID: 12123628
[TBL] [Abstract][Full Text] [Related]
34. Effect of silymarin on the oral bioavailability of ranitidine in healthy human volunteers.
Rao BN; Srinivas M; Kumar YS; Rao YM
Drug Metabol Drug Interact; 2007; 22(2-3):175-85. PubMed ID: 17708067
[TBL] [Abstract][Full Text] [Related]
35. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
[TBL] [Abstract][Full Text] [Related]
36. Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers.
Yan M; Fang PF; Li HD; Xu P; Liu YP; Wang F; Cai HL; Tan QY
Eur J Clin Pharmacol; 2013 Mar; 69(3):515-21. PubMed ID: 22983284
[TBL] [Abstract][Full Text] [Related]
37. The influence of modulation of P-glycoprotein and /or cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered morphine in dogs.
Gadeyne C; Van der Heyden S; Gasthuys F; Croubels S; Schauvliege S; Polis I
J Vet Pharmacol Ther; 2011 Oct; 34(5):417-23. PubMed ID: 21241325
[TBL] [Abstract][Full Text] [Related]
38. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
39. The Effect of P-Glycoprotein Inhibition and Activation on the Absorption and Serum Levels of Cyclosporine and Tacrolimus in Rats.
Yigitaslan S; Erol K; Cengelli C
Adv Clin Exp Med; 2016; 25(2):237-42. PubMed ID: 27627555
[TBL] [Abstract][Full Text] [Related]
40. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]